U.S. flag An official website of the United States government
  1. Home
  2. Vaccines, Blood & Biologics
  3. Cellular & Gene Therapy Products
  4. CBER Regenerative Medicine Advanced Therapy (RMAT) Approvals
  1. Cellular & Gene Therapy Products

CBER Regenerative Medicine Advanced Therapy (RMAT) Approvals

Data as of December 31, 2022

Application Number Submission Type
and Number
Proprietary Name Established Name Applicant Approval Date Use
BLA 125685 ORIGINAL-1 RETHYMIC Allogeneic processed Thymus Tissue Enzyvant Therapeutics GmbH 08-Oct-2021 Immune reconstitution in pediatric patients with congenital athymia.
BLA 125730 ORIGINAL-1 StrataGraft Allogeneic Keratinocyte Cell Line (NIKS), Seeded on Rat Collagen (BD) Conditioned with Human Dermal Fibroblasts (Clonetics) Stratatech Corporation 15-Jun-2021 Indicated to promote durable wound closure & regenerative healing in the treatment of adult patients with debrided thermal burns that contain intact dermal elements, and for which surgical intervention is clinically indicated.

BLA 125714



lisocabtagene maraleucel

Juno Therapeutics, a Celgene Company


Treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies.

* RMAT designation was enacted in the 21st Century Cures Act on December 13, 2016.

Resources for You

Back to Top